TRIAL DETAIL
Temozolomide in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Temozolomide in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Completed |
|||
Phase: |
2 |
Start Date 04/01/2000 |
Age of Trial (yrs) 24.1 |
|
Treatment Phase: |
First-line |
|||
Drug Category: |
SDH-directed |
|||
Strategy: |
Interfere with DNA replication |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
CDR0000067710, SWOG-S9926 |
|||
Sponsor: |
SWOG,
NCI |
|||
Patient Contact: |
||||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Intravenous |
|||
Trial Notes: |
Study Chair: Mark M. Zalupski, MD University of Michigan Cancer Center This phase II trial is complete.This sarcoma trial included 19 GIST patients, the median time to disease progression was 2.3 months in patients with GISTs and 3.3 months in patients with other STSs (see the trial results link). The authors conclusions were: The data from the current study suggest that temozolomide is well tolerated but has only minimal efficacy and a limited role in the treatment of patients with STSs. |
|||
Trial Links |
Trial Results |
Drug Information |
| Temodar prescribing information |
| Temozolomide - Wikipedia |
| NCI - Temozolomide |
| U.S. National Library of Medicine - Drug Info |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |